Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Qu, Xiaoyan ^a   Du, Juan ^a   Zhang, Chunyang ^a   Fu, Weijun ^a   Xi, Hao ^a   Zou, Jianfeng ^a   Hou, Jian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; ARSENIC TRIOXIDE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 6; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; I KAPPA B KINASE; ORGANOARSENIC DERIVATIVE; OXIDE; TUBULIN;

ACETYLATION; ANTIMYELOMA EFFECT; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MYELOMA CELL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; METABOLISM; MULTIPLE MYELOMA; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL LINE, TUMOR; CELL SURVIVAL; CYTOPLASM; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; I-KAPPA B KINASE; IMMUNOPRECIPITATION; MULTIPLE MYELOMA; OXIDES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUBULIN;

EID: 84863175278     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032215     Document Type: Article

References (42)

1. Wang ZY, Chen Z, (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: 2505-2515.
2. Sanz MA, Lo-Coco F, (2011) Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 29: 495-503.
3. Emadi A, Gore SD, (2010) Arsenic trioxide- An old drug rediscovered. Blood Rev 24: 191-199.
4. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, et al. (2008) Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14: 1401-1407.
5. Vey N, Bosly A, Guerci A, Feremans W, Dombret H, et al. (2006) Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 24: 2465-2471.
6. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL Jr, et al. (2011) A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. LID- 10.1002/cncr.26517 [doi]. Cancer.
7. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S, (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62: 3893-3903.
8. Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, et al. (2002) Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 1: 851-860.
9. Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, et al. (2011) Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest 121: 148-160.
10. Dos SGA, Abreu ELRS, Pestana CR, Lima AS, Scheucher PS, et al. (2011) (+)alpha-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo. LID- 10.1038/leu.2011.216 [doi]. Leukemia.
11. Lemoine M, Younes A, (2010) Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med 10: 462-470.
12. Aldana-Masangkay GI, Sakamoto KM, (2011) The role of HDAC6 in cancer. J Biomed Biotechnol 2011: 875824.
13. Gregoretti IV, Lee YM, Goodson HV, (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17-31.
14. Verdin E, Dequiedt F, Kasler HG, (2003) Class II histone deacetylases: versatile regulators. Trends Genet 19: 286-293.
15. Tokesi N, Lehotzky A, Horvath I, Szabo B, Olah J, et al. (2010) TPPP/p25 promotes tubulin acetylation by inhibiting histone deacetylase 6. J Biol Chem 285: 17896-17906.
16. Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez-Madrid F, (2008) HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol 18: 291-297.
17. Yao YL, Yang WM, (2011) Beyond histone and deacetylase: an overview of cytoplasmic histone deacetylases and their nonhistone substrates. J Biomed Biotechnol 2011: 146493.
18. Hinz M, Broemer M, Arslan SC, Otto A, Mueller EC, et al. (2007) Signal responsiveness of IkappaB kinases is determined by Cdc37-assisted transient interaction with Hsp90. J Biol Chem 282: 32311-32319.
19. Qing G, Yan P, Xiao G, (2006) Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IkappaB kinase (IKK). Cell Res 16: 895-901.
20. Gupta SC, Sundaram C, Reuter S, Aggarwal BB, (2010) Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 1799: 775-787.
21. Hayden MS, Ghosh S, (2008) Shared principles in NF-kappaB signaling. Cell 132: 344-362.
22. Bohuslav J, Chen LF, Kwon H, Mu Y, Greene WC, (2004) p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem 279: 26115-26125.
23. Waxman S, Anderson KC, (2001) History of the development of arsenic derivatives in cancer therapy. Oncologist 6 (Suppl 2): 3-10.
24. Kajiguchi T, Yamamoto K, Iida S, Ueda R, Emi N, et al. (2006) Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer Sci 97: 540-545.
25. Wen J, Cheng HY, Feng Y, Rice L, Liu S, et al. (2008) P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol 140: 169-180.
26. Roussel RR, Barchowsky A, (2000) Arsenic inhibits NF-kappaB-mediated gene transcription by blocking IkappaB kinase activity and IkappaBalpha phosphorylation and degradation. Arch Biochem Biophys 377: 204-212.
27. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, et al. (2000) Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 275: 36062-36066.
28. Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, et al. (2003) Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 101: 4576-4582.
29. Drobna Z, Jaspers I, Thomas DJ, Styblo M, (2003) Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB J 17: 67-69.
30. Davison K, Mann KK, Waxman S, Miller WH Jr, (2004) JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 103: 3496-3502.
31. Sharma V, Koul N, Joseph C, Dixit D, Ghosh S, et al. (2010) HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. J Cell Mol Med 14: 2151-2161.
32. Baysan A, Yel L, Gollapudi S, Su H, Gupta S, (2007) Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells. Int J Oncol 30: 313-318.
33. Zhou L, Jing Y, Styblo M, Chen Z, Waxman S, (2005) Glutathione-S-transferase pi inhibits As2O3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism. Blood 105: 1198-1203.
34. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, et al. (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115: 727-738.
35. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, et al. (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458.
36. Wu KL, Beksac M, van DJ, Amadori S, Zweegman S, et al. (2006) Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica 91: 1722-1723.
37. Boyault C, Sadoul K, Pabion M, Khochbin S, (2007) HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 26: 5468-5476.
38. Criollo A, Senovilla L, Authier H, Maiuri MC, Morselli E, et al. (2010) The IKK complex contributes to the induction of autophagy. EMBO J 29: 619-631.
39. Gao YS, Hubbert CC, Lu J, Lee YS, Lee JY, et al. (2007) Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol 27: 8637-8647.
40. Karin M, (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
41. Thu YM, Richmond A, (2010) NF-kappaB inducing kinase: a key regulator in the immune system and in cancer. Cytokine Growth Factor Rev 21: 213-226.
42. Sakurai H, Suzuki S, Kawasaki N, Nakano H, Okazaki T, et al. (2003) Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 278: 36916-36923.